Company registration number 10512894 (England and Wales)
PETER JENKINS ONCOLOGY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
PETER JENKINS ONCOLOGY LIMITED
CONTENTS
Page
Statement of financial position
1
Notes to the financial statements
2 - 3
PETER JENKINS ONCOLOGY LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
31 DECEMBER 2025
31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Current assets
Debtors
71,593
25,205
Cash at bank and in hand
1,203,298
1,012,304
1,274,891
1,037,509
Creditors: amounts falling due within one year
(100,951)
(66,602)
Net current assets
1,173,940
970,907
Capital and reserves
Called up share capital
3
100
100
Profit and loss reserves
1,173,840
970,807
Total equity
1,173,940
970,907

For the financial year ended 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with section 444 of the Companies Act 2006, all of the members of the company have consented to the preparation of abridged financial statements pursuant to paragraph 1A of Schedule 1 to the Small Companies and Groups (Accounts and Directors’ Report) Regulations (SI 2008/409)(b).

The director of the company has elected not to include a copy of the income statement within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 9 September 2026
Dr P J Jenkins
Director
Company registration number 10512894 (England and Wales)
PETER JENKINS ONCOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
1
Accounting policies
Company information

Peter Jenkins Oncology Limited is a private company limited by shares incorporated in England and Wales. The registered office is 6 Manor Park Business Centre, Mackenzie Way, Cheltenham, Gloucestershire, England, GL51 9TX.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

These financial statements are prepared on the going concern basis. The director has a reasonable expectation that the company will continue in operational existence for the foreseeable future. However, the director is aware of certain material uncertainties which may cause doubt on the company's ability to continue as a going concern.

1.3
Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

 

Turnover is recognised when an invoice is raised.

1.4
Taxation

The tax expense represents the sum of the tax currently payable.

Current tax

Taxation for the year comprises current tax only. Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
1
1
PETER JENKINS ONCOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -
3
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A of £1 each
45
45
45
45
Ordinary B of £1 each
45
45
45
45
Ordinary C of £1 each
5
5
5
5
Ordinary D of £1 each
5
5
5
5
100
100
100
100
4
Directors' transactions

Dr P J Jenkins

Director and shareholder

 

In a previous period, Dr Jenkins lent the company £8,815 for working capital. During the year, the director lent further sums, The amount due to the director at year end was £11,106 (2024: £8,815). The loan is unsecured, interest free and repayable on demand.

2025-12-312025-01-01falsefalsefalse09 September 2026CCH SoftwareCCH Accounts Production 2026.200No description of principal activityDr P J JenkinsDr S Freeman105128942025-01-012025-12-31105128942025-12-3110512894core:WithinOneYear2025-12-3110512894core:WithinOneYear2024-12-31105128942024-12-3110512894core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3110512894core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3110512894core:ShareCapital2025-12-3110512894core:ShareCapital2024-12-3110512894core:RetainedEarningsAccumulatedLosses2025-12-3110512894core:RetainedEarningsAccumulatedLosses2024-12-3110512894core:ShareCapitalOrdinaryShareClass12025-12-3110512894core:ShareCapitalOrdinaryShareClass12024-12-3110512894core:ShareCapitalOrdinaryShareClass22025-12-3110512894core:ShareCapitalOrdinaryShareClass22024-12-3110512894core:ShareCapitalOrdinaryShareClass32025-12-3110512894core:ShareCapitalOrdinaryShareClass32024-12-3110512894core:ShareCapitalOrdinaryShareClass42025-12-3110512894core:ShareCapitalOrdinaryShareClass42024-12-3110512894core:ShareCapitalOrdinaryShares2025-12-3110512894core:ShareCapitalOrdinaryShares2024-12-3110512894bus:Director12025-01-012025-12-3110512894bus:OrdinaryShareClass12025-01-012025-12-3110512894bus:OrdinaryShareClass22025-01-012025-12-3110512894bus:OrdinaryShareClass32025-01-012025-12-3110512894bus:OrdinaryShareClass42025-01-012025-12-3110512894bus:OrdinaryShareClass12025-12-3110512894bus:OrdinaryShareClass12024-12-3110512894bus:OrdinaryShareClass22025-12-3110512894bus:OrdinaryShareClass22024-12-3110512894bus:OrdinaryShareClass32025-12-3110512894bus:OrdinaryShareClass32024-12-3110512894bus:OrdinaryShareClass42025-12-3110512894bus:OrdinaryShareClass42024-12-3110512894bus:AllOrdinaryShares2025-12-3110512894bus:AllOrdinaryShares2024-12-3110512894bus:PrivateLimitedCompanyLtd2025-01-012025-12-3110512894bus:SmallCompaniesRegimeForAccounts2025-01-012025-12-3110512894bus:FRS1022025-01-012025-12-3110512894bus:AuditExemptWithAccountantsReport2025-01-012025-12-3110512894bus:CompanySecretary12025-01-012025-12-3110512894bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP